Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
- LOS ANGELES (AP) — Shohei Ohtani’s first walk-off hit for the Los Angeles Dodgers was also his first2024-05-22
What is happening with the NZ housing market this week?
Home values in Auckland fell in the past three months. Photo: RNZ / Dan Cook2024-05-22VOX POPULI: Kishida’s gift of cherry seedlings to the U.S. raises uneasy feeling
In 1912, the final year of the Meiji Era that began in 1868, it is said that vehement opposition was2024-05-22Pseudoephedrine could be back on the shelves as soon as June
Associate Health Minister David Seymour. Photo: RNZ / Angus Dreaver2024-05-22The unstoppable duo of Emma Stone and Yorgos Lanthimos
CANNES, France (AP) — Before a journalist has even lobbed a question, Emma Stone and Yorgos Lanthimo2024-05-22Crash snarls Auckland Harbour Bridge traffic
Photo: Supplied / Waka Kotahi2024-05-22
atest comment